Prior authorization is one of the most common — and frustrating — barriers between a diabetes patient and the medication their doctor prescribed. Insurers use PA to control costs on expensive drugs, ensure clinical appropriateness, and enforce step therapy. For diabetes, this hits GLP-1 receptor agonists like Ozempic and Mounjaro, SGLT2 inhibitors like Jardiance, CGMs, insulin pumps, and brand-name drugs when generics exist. Done right, the PA process takes a week or two and gets approved. Done wrong, it drags into months of delays and rejected appeals. This guide walks through 2026 PA strategy for diabetes drugs.
What Triggers Prior Authorization
- GLP-1 receptor agonists — Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Rybelsus, Victoza, Byetta
- SGLT2 inhibitors — Jardiance, Farxiga, Invokana, Steglatro
- DPP-4 inhibitors (some plans) — Januvia (before generic), Tradjenta, Onglyza
- Long-acting basal analog insulins on certain plans — Tresiba, Toujeo
- Continuous glucose monitors — Dexcom, Libre, Eversense
- Insulin pumps — Tandem, Omnipod, Medtronic, Beta Bionics
- Brand-name drugs when generic available — pharmacist may auto-substitute, but brand request triggers PA
- Off-label uses — e.g., Wegovy for diabetes (off-label, technically), tirzepatide for type 1
- High-dose or non-standard regimens — quantity limits beyond formulary norms
Documentation Required for Common Diabetes PAs
| Drug/Device | Required Documentation |
|---|---|
| Ozempic / Mounjaro / Trulicity | Type 2 diabetes diagnosis (ICD-10), current A1C, BMI, prior trial of metformin (or contraindication), clinical goals |
| Wegovy / Zepbound for weight loss | BMI ≥30 or ≥27 with comorbidity, prior weight loss attempts, clinical goals |
| Jardiance / Farxiga | Type 2 diabetes diagnosis, A1C above target, prior medication trials, sometimes cardiovascular or kidney disease documentation |
| CGM (Dexcom / Libre) | Diabetes diagnosis, insulin use OR hypoglycemia history, frequent SMBG documentation, follow-up plan |
| Insulin pump | Diagnosis, current MDI regimen, frequent SMBG, A1C >8%, C-peptide (Medicare), education completion |
| Tresiba / Toujeo / Lantus | Diabetes diagnosis, A1C, prior insulin trial (some plans), insurance formulary tier rules |
Step Therapy
Step therapy (“fail first”) is the insurer’s rule that you must try and fail cheaper alternatives before being approved for an expensive brand drug. Typical diabetes step therapy ladders:
| Target Drug | Step 1 (Cheapest) | Step 2 | Step 3 (Target) |
|---|---|---|---|
| GLP-1 (Ozempic, Mounjaro) | Metformin | Sulfonylurea (glipizide) or DPP-4 (sitagliptin) | GLP-1 approval |
| SGLT2 (Jardiance, Farxiga) | Metformin | Sulfonylurea or DPP-4 | SGLT2 approval |
| Brand Lantus | Insulin Glargine biosimilar (Semglee, Rezvoglar) | — | Brand Lantus PA |
| Tresiba | Lantus / Toujeo / biosimilar glargine | — | Tresiba PA |
Step Therapy Exceptions
- Contraindication to step 1 drug (renal failure for metformin, allergy to sulfonylurea)
- Prior failure or intolerance documented in chart
- Clinical urgency (cardiovascular event making SGLT2 first-line under guidelines)
- Pregnancy or other special clinical situation
- Type 1 diabetes (sulfonylureas inappropriate)
Your clinician documents the exception reason on the PA form; most are approved when properly documented.
The PA Submission Process
- Clinician writes prescription
- Pharmacy attempts to fill; insurance returns “prior authorization required” rejection
- Pharmacy notifies prescriber’s office
- Prescriber’s office submits PA via electronic system, fax, or insurance portal
- Insurance reviews — typically 5 to 14 days
- Approval letter sent to prescriber, patient, and pharmacy
- Pharmacy fills the prescription
- PA renewals required annually for most drugs; some longer for stable patients
Standard vs Expedited PA Timelines
| Decision Type | Medicare | Commercial | Medicaid |
|---|---|---|---|
| Standard PA | 72 hours | 5 to 14 business days | Varies by state; usually 5 to 14 days |
| Expedited PA | 24 hours | 24 to 72 hours | 24 to 72 hours |
| Standard appeal (level 1) | 7 days | 30 days (typical) | 30 days |
| Expedited appeal | 72 hours | 72 hours | 72 hours |
| External review | 60 days | 30 to 60 days | Varies |
What “Medical Necessity” Means in PA
- The drug is FDA-approved or evidence-supported for your specific condition
- It matches current clinical guidelines (ADA Standards of Care in diabetes)
- You have failed or are intolerant to cheaper alternatives
- The dose and quantity match standard practice
- No safer or cheaper alternative is appropriate
- Failure to provide the drug would harm your health (delayed care, complication risk)
Your clinician’s letter of medical necessity should hit each of these points specifically.
The Four-Step Appeal Process
Step 1: Internal Redetermination
Request the insurance plan to reconsider the denial. Submit additional documentation: clinician letter explaining medical necessity, lab work, prior treatment failures, peer-reviewed evidence supporting the drug for your situation. Timeline: 30 days for standard, 72 hours for expedited.
Step 2: Second Internal Review
If step 1 fails, request review by a different reviewer (or a peer-to-peer review where your clinician speaks directly to the insurance medical director). Timeline: 30 days standard, 72 hours expedited.
Step 3: External Independent Review
An independent third-party reviewer evaluates the case. Insurance plans must comply with their decision under the ACA and state laws. Free for the patient. Timeline: 30 to 60 days standard. About 60 to 70 percent of external reviews favor the patient when documentation is strong.
Step 4: State Insurance Commissioner Complaint
For state-regulated plans (not Medicare or self-funded ERISA employer plans), file a complaint with your state insurance department. They have enforcement authority. For Medicare and ERISA plans, the process ends at external review.
What to Include in a Strong Appeal
- Clinician letter explaining: diagnosis, current treatment, why standard alternatives failed or are contraindicated, why the requested drug is medically necessary, expected outcomes
- Clinical guidelines citation (ADA Standards of Care, NIH guidelines)
- Recent lab results (A1C, kidney function, weight, BMI)
- Medication history with dates and outcomes
- Patient impact statement (your own letter describing your experience)
- Peer-reviewed evidence supporting the drug for your indication
- Pharmacy fill history showing tried-and-failed alternatives
While the PA Is Pending
- Ask the pharmacy about a 3- to 5-day emergency supply (most plans allow this for insulin and critical drugs)
- Use manufacturer programs — Lilly $35 Insulin Value Program, NovoCare, Sanofi Valyou — see our manufacturer assistance guide
- Check GoodRx cash prices for the drug — sometimes cheaper than insurance copay
- Consider Walmart’s $4 generic list for older alternatives
- Ask your prescriber for samples to bridge the gap
- For ReliOn insulin at Walmart, no Rx needed for short-acting insulin in most states
Working With Your Clinician’s Staff
- Many clinics have dedicated PA coordinators or pharmacy techs who handle submissions
- Sign release forms allowing pharmacist or PA coordinator to discuss your case directly with insurance
- Provide them current insurance card and any updates promptly
- Ask for a copy of the PA submission for your records
- If your PA coordinator is slow, ask to speak with the practice manager about expediting
- For complex cases, consider working with a patient advocate or hiring a service like Healthcare.gov navigator
Common Reasons for PA Denial — and What to Do
| Denial Reason | Response |
|---|---|
| “Step therapy not completed” | Document prior failures or contraindications |
| “Diagnosis not supported” | Submit ICD-10 code and clinical notes |
| “Off-label use” | Cite FDA approval, guideline, or peer-reviewed evidence |
| “Quantity limit exceeded” | Document dose-response and clinical rationale |
| “Drug not on formulary” | Request formulary exception or switch to covered alternative |
| “Not medically necessary” | Submit medical necessity letter with full clinical context |
| “Lab work outdated” | Submit current A1C, lipids, kidney function |
Sample Medical Necessity Letter Components
- Patient identifying information — name, DOB, insurance member ID
- Specific drug requested — with strength, dose, frequency, quantity
- Diagnosis — with ICD-10 code
- Clinical history — duration of diabetes, current A1C, complications, prior treatments and outcomes
- Reason for this drug — why standard alternatives are inappropriate; clinical goals (target A1C, weight, cardiovascular protection)
- Supporting evidence — ADA guideline citation, recent lab values, comorbidities
- Statement of medical necessity — explicit statement that this drug is necessary for the patient’s health
- Prescriber signature and credentials
Common Pitfalls
- Letting PA expire and not realizing supply has stopped
- Not knowing PA is needed until pharmacy denies fill — slows process
- Assuming initial denial is final — most can be appealed
- Not getting a peer-to-peer review when offered
- Missing expedited review for urgent cases
- Forgetting that some plans have different rules for mail-order than retail
- Not documenting prior medication failures in the chart at the time they happened
Patient Advocate and Navigation Resources
- Patient Advocate Foundation — free case management for chronic disease patients including diabetes
- Patient Access Network (PAN) Foundation — assistance with copays plus advocacy
- State insurance commissioner — for state-regulated plan complaints
- 1-800-MEDICARE — Medicare appeal assistance
- HealthCare.gov navigators — for Marketplace plan issues
- State Health Insurance Assistance Program (SHIP) — Medicare assistance
Related Reading
See CGM insurance coverage, insulin pump insurance coverage, manufacturer assistance programs, Medicare diabetes coverage, generic vs brand diabetes drugs, and our treatment hub.
The Bottom Line
Prior authorization is the most common barrier between diabetes patients and the drugs their doctors prescribe. It hits GLP-1 receptor agonists, SGLT2 inhibitors, CGMs, insulin pumps, and brand-name drugs when generics are available. Done well — with current labs, documented prior medication trials, a clear letter of medical necessity, and step therapy contraindications spelled out — about 70 to 80 percent of diabetes PAs are approved on first submission. For the 20 to 30 percent denied initially, the four-step appeals process (internal redetermination, second internal review, external independent review, state commissioner complaint) overturns about 60 to 70 percent. Standard PA decisions take 5 to 14 days; expedited cases get 24- to 72-hour turnaround. While waiting, manufacturer programs, GoodRx, Walmart’s $4 list, and emergency pharmacy supplies can fill gaps. Work closely with your clinician’s PA coordinator, document medication failures in the chart as they happen, and do not accept the first denial as the final answer. Talk to your prescriber about which appeal strategy fits your case.
